MX2024009559A - Métodos de tratamiento mediante el uso de moduladores del canal de calcio tipo t. - Google Patents

Métodos de tratamiento mediante el uso de moduladores del canal de calcio tipo t.

Info

Publication number
MX2024009559A
MX2024009559A MX2024009559A MX2024009559A MX2024009559A MX 2024009559 A MX2024009559 A MX 2024009559A MX 2024009559 A MX2024009559 A MX 2024009559A MX 2024009559 A MX2024009559 A MX 2024009559A MX 2024009559 A MX2024009559 A MX 2024009559A
Authority
MX
Mexico
Prior art keywords
calcium channel
type calcium
methods
treatment
channel modulators
Prior art date
Application number
MX2024009559A
Other languages
English (en)
Spanish (es)
Inventor
Bernard Ravina
Original Assignee
Praxis Prec Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Prec Medicines Inc filed Critical Praxis Prec Medicines Inc
Publication of MX2024009559A publication Critical patent/MX2024009559A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2024009559A 2022-02-03 2023-02-03 Métodos de tratamiento mediante el uso de moduladores del canal de calcio tipo t. MX2024009559A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263306340P 2022-02-03 2022-02-03
PCT/US2023/061973 WO2023150703A2 (en) 2022-02-03 2023-02-03 Methods of treatment using t-type calcium channel modulators

Publications (1)

Publication Number Publication Date
MX2024009559A true MX2024009559A (es) 2024-09-23

Family

ID=87552982

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024009559A MX2024009559A (es) 2022-02-03 2023-02-03 Métodos de tratamiento mediante el uso de moduladores del canal de calcio tipo t.

Country Status (10)

Country Link
US (1) US20250170114A1 (cg-RX-API-DMAC10.html)
EP (1) EP4472633A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025505578A (cg-RX-API-DMAC10.html)
KR (1) KR20240144291A (cg-RX-API-DMAC10.html)
CN (1) CN118785905A (cg-RX-API-DMAC10.html)
AU (1) AU2023216271A1 (cg-RX-API-DMAC10.html)
CA (1) CA3243616A1 (cg-RX-API-DMAC10.html)
IL (1) IL314576A (cg-RX-API-DMAC10.html)
MX (1) MX2024009559A (cg-RX-API-DMAC10.html)
WO (1) WO2023150703A2 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025188619A1 (en) * 2024-03-04 2025-09-12 Praxis Precision Medicines, Inc. Methods of treating parkinson's disease with t-type calcium channel modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009500340A (ja) * 2005-06-29 2009-01-08 メルク エンド カムパニー インコーポレーテッド 4−フルオロ−ピペリジンt型カルシウムチャネルアンタゴニスト
RU2746188C2 (ru) * 2015-11-12 2021-04-08 Афаски, Инк. Ингибиторы ионного канала, фармацевтические составы и применение
US11744825B2 (en) * 2018-08-28 2023-09-05 Afasci, Inc. Methods of treating hypersensitive cough or itching using ion channel inhibitory compounds
WO2021007487A1 (en) * 2019-07-11 2021-01-14 Praxis Precision Medicines, Inc. Formulations of t-type calcium channel modulators and methods of use thereof
CN115776894A (zh) * 2020-04-29 2023-03-10 普拉西斯精密医药公司 T型钙通道调节剂的使用方法
JP7841757B2 (ja) * 2020-11-09 2026-04-07 プラクシス プレシジョン メディシンズ, インコーポレイテッド T型カルシウムチャネル調節因子及びその使用方法
US20250295646A1 (en) * 2022-05-09 2025-09-25 Praxis Precision Medicines, Inc. Methods of use of t-type calcium channel modulators

Also Published As

Publication number Publication date
EP4472633A2 (en) 2024-12-11
AU2023216271A1 (en) 2024-08-15
WO2023150703A3 (en) 2023-09-14
JP2025505578A (ja) 2025-02-28
US20250170114A1 (en) 2025-05-29
CN118785905A (zh) 2024-10-15
WO2023150703A2 (en) 2023-08-10
EP4472633A4 (en) 2026-01-14
IL314576A (en) 2024-09-01
CA3243616A1 (en) 2023-08-10
KR20240144291A (ko) 2024-10-02

Similar Documents

Publication Publication Date Title
ZA202109010B (en) Compounds and methods for the treatment of covid-19
MX2023005455A (es) Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil.
MX2025005489A (es) Uso de lumateperona para el tratamiento del trastorno bipolar ii
PH12022552702A1 (en) Methods of treating diabetic kidney disease
MX2022011804A (es) Uso de agentes para el tratamiento de condiciones respiratorias.
WO2020033838A3 (en) Treatment of egfr-mutant cancer
PH12021553102A1 (en) Methods of treating fabry disease in patients having renal impairment
MX2022011041A (es) Tratamiento de dolor y vasoconstriccion.
WO2022047128A3 (en) Method for treating complement mediated disorders caused by betacoronaviruses
MX2021005967A (es) Formas purificadas de rofecoxib, métodos de fabricación y uso.
PH12023550780A1 (en) Line-1 inhibitors to treat disease
MX2022011490A (es) Tratamiento o metodo de prevencion de falla cardiaca cronica.
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
WO2023150703A3 (en) Methods of treatment using t-type calcium channel modulators
MX2020013692A (es) Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
MX2022012001A (es) Tratamiento preventivo de la migra?a.
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
MX2008002456A (es) Uso de ambroxol para el tratamiento de infecciones por rinovirus.
MX2024000081A (es) Derivados de cannabicromeno y métodos para fabricar y usar los mismos.
WO2022221349A3 (en) Methods and compositions for treating long covid-19
WO2025058667A3 (en) Prevention and treatment of conditions using ethyl pyruvate
MX2025013588A (es) Tratamiento a largo plazo contra la pérdida de cabello
MX2024015824A (es) Metodos para el tratamiento o la prevencion del sindrome de vejiga hiperactiva
MX2024002602A (es) Métodos para prevenir y tratar el dolor y síntomas asociados.
MX2023013065A (es) Moduladores de canales de potasio de gran conductancia, composiciones de estos, métodos para su fabricación y métodos para su uso.